<DOC>
	<DOCNO>NCT00741793</DOCNO>
	<brief_summary>This registry multi-center , prospective , longitudinal , observational program gather analyse data participant treat infliximab , golimumab , golimumab Intravenous ( I.V ) ustekinumab . Treatment prescribe physician accord actual clinical practice standard care Rheumatoid Arthritis ( RA ) , Axial Spondyloarthritis ( AxSpA ) , Psoriatic Arthritis ( PsA ) ; randomize assignment treatment . At baseline approximately every 6 month thereafter , information collect ass safety , clinical outcome , quality life , comorbidities , pharmacoeconomics treatment regimens among cohort participant receive infliximab , golimumab , golimumab I.V ustekinumab treatment RA , AxSpA PsA .</brief_summary>
	<brief_title>Biologic Treatment Registry Across Canada</brief_title>
	<detailed_description>Participants select registry use non-probability sampling method .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Participant start infliximab , golimumab , golimumab Intravenous ( I.V ) ustekinumab time enrollment biologic naive treat one prior biologic ( include infliximab , golimumab , golimumab I.V ustekinumab ) prior enrollment Participant sign approve informed consent form Participant diagnose RA , AxSpA PsA eligible treatment infliximab , golimumab , golimumab I.V ustekinumab accordance routine clinical care Canadian Product Monograph . Participant treat two biologics , period time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid arthritis ; psoriatic arthritis ; axial spondyloarthritis</keyword>
	<keyword>Remicade速</keyword>
	<keyword>Simponi速</keyword>
	<keyword>Simponi速 I.V</keyword>
	<keyword>Stelara速</keyword>
	<keyword>Registry</keyword>
	<keyword>BioTRAC</keyword>
</DOC>